{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:47:11Z","timestamp":1773798431533,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006023","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000}}],"reference-count":110,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006023.pub2","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T18:36:55Z","timestamp":1296844615000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phosphate binders for preventing and treating bone disease in chronic kidney disease patients"],"prefix":"10.1002","author":[{"given":"Sankar D","family":"Navaneethan","sequence":"first","affiliation":[{"name":"Glickman Urological and Kidney institute, Cleveland Clinic; Department of Nephrology and Hypertension; Cleveland OH USA 44195"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacristina","family":"Vecchio","sequence":"additional","affiliation":[{"name":"Mario Negri Sud Consortium; Clinical Pharmacology and Epidemiology; Via Nazionale 8\/A Santa Maria Imbaro Chieti Italy 66030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"b) Sydney School of Public Health, The University of Sydney; a) Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead; Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grahame J","family":"Elder","sequence":"additional","affiliation":[{"name":"b) Osteoporosis and Bone Biology Program, Garvan Institute of Medical Research; a) Department of Renal Medicine, Westmead Hospital; 384 Victoria St Darlinghurst NSW Australia 2010"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"b) Sydney School of Public Health, University of Sydney, Australia, c) Diaverum Medical-Scientific Office; a) Mario Negri Sud Consortium, Santa Maria Imbaro (Ch), Italy; Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ndt\/gfh693","article-title":"Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study","volume":"20","author":"Al-Baaj","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000168713","article-title":"Calcium acetate versus calcium carbonate for the control of serum phosphorus in haemodialysis patients","volume":"14","author":"Almirall","year":"1994","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/ndt\/14.6.1475","article-title":"Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study","volume":"14","author":"Birck","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in haemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident haemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to haemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0007|cit7","first-page":"348","article-title":"A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis","volume":"20","author":"Borrego","year":"2000","journal-title":"Nefrologia"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0008|cit8","first-page":"c273","article-title":"Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1542-4758.2009.00369.x","article-title":"Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients","volume":"13","author":"Peres","year":"2009","journal-title":"Hemodialysis International"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ajkd.1998.v31.pm9469496","article-title":"Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic haemodialysis","volume":"31","author":"Bro","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000186802","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients","volume":"60","author":"Caravaca","year":"1992","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in haemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","article-title":"Poly(allylamine hydrochloride) (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure","volume":"29","author":"Chertow","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0016|cit16","first-page":"18","article-title":"A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in haemodialysis patients","volume":"51","author":"Chertow","year":"1999","journal-title":"Clinical Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","article-title":"Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density","volume":"20","author":"Asmus","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","article-title":"Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients","volume":"149","author":"Ferramosca","year":"2005","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/JBMR.041221","article-title":"Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis","volume":"20","author":"Raggi","year":"2005","journal-title":"Journal of Bone & Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5414\/CNP63461","article-title":"Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease","volume":"63","author":"Chiang","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1590\/S1516-31802000000600006","article-title":"Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients","volume":"118","author":"d'Almeida Filho","year":"2000","journal-title":"Revista Paulista de Medicina [Sao Paulo Medical Journal]"},{"issue":"85","key":"10.1002\/14651858.CD006023.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","author":"D'Haese","year":"2003","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0024|cit24","unstructured":"Wilson R Spica Consultants Ltd Personal communication 2005"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0026|cit26","first-page":"S108","article-title":"Sevelamer worsens metabolic acidosis in hemodialysis patients","volume":"19 Suppl 9","author":"Santo","year":"2006","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0027|cit27","first-page":"680","article-title":"Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract]","volume":"18 Suppl 4","author":"Deuber","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"17","author":"Emmett","year":"1991","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/ndt\/gfp372","article-title":"A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis","volume":"24","author":"Fan","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in haemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.ki.5001932","article-title":"Cognitive function in Stage 5 chronic kidney disease patients on haemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy","volume":"71","author":"Altmann","year":"2007","journal-title":"Kidney International."},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5414\/CNP62193","article-title":"Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis","volume":"62","author":"Finn","year":"2004","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/j.ajkd.2006.05.026","article-title":"Results of a randomized crossover study comparing once daily and thrice-daily sevelamer dosing","volume":"48","author":"Fischer","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2215\/CJN.04741107","article-title":"Higher strength lanthanum carbonate provides serum phosphorus control with a low\u00a0tablet burden and is preferred by patients and physicians: a multicenter study","volume":"3","author":"Mehrotra","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0036|cit36","first-page":"746A","article-title":"Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]","volume":"16","author":"Gallieni","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"85","key":"10.1002\/14651858.CD006023.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate","author":"Hervas","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0038|cit38","first-page":"c8","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6-month, randomized, comparative trial versus Calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0039|cit39","first-page":"c61","article-title":"Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study","volume":"102","author":"Hutchison","year":"2006","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1744-9987.2008.00557.x","article-title":"Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis","volume":"12","author":"Itoh","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01666818","article-title":"Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional Aluminium hydroxide on hyperaluminaemia","volume":"69","author":"Ittel","year":"1991","journal-title":"Klinische Wochenschrift"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0042|cit42","first-page":"111","article-title":"Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients","volume":"45","author":"Janssen","year":"1996","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ndt\/6.2.98","article-title":"Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients","volume":"6","author":"Jespersen","year":"1991","journal-title":"Nephology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006023.pub2-BIB0045|cit45","first-page":"755A","article-title":"Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients - a randomized, open label, dose titration study of PB-94 versus caltan\u00ae tablet 500 (calcium carbonate) [abstract]","volume":"12","author":"Kinugasa","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ndt\/gfh632","article-title":"Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial","volume":"20","author":"Kurihara","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/08860220600925388","article-title":"A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients","volume":"28","author":"Liu","year":"2006","journal-title":"Renal Failure"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0049|cit49","first-page":"284","article-title":"Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years","volume":"70","author":"Malluche","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2215\/CJN.02630608","article-title":"Iron-magnesium hydroxycarbonate (Fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients","volume":"4","author":"McIntyre","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis","volume":"9","author":"Pflanz","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5-6","key":"10.1002\/14651858.CD006023.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000065273","article-title":"Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure","volume":"22","author":"Phelps","year":"2002","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0053|cit53","first-page":"341","article-title":"Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study","volume":"8","author":"Ring","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0272-6386(89)80052-6","article-title":"Phosphate-binding effects of sucralfate in patients with chronic renal failure","volume":"13","author":"Roxe","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0055|cit55","first-page":"130","article-title":"Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study","volume":"20","author":"Rudnicki","year":"1994","journal-title":"Mineral & Electrolyte Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients An open-label, randomized study","volume":"18","author":"Sadek","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0058|cit58","first-page":"26","article-title":"Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis","volume":"19","author":"Saif","year":"2007","journal-title":"Journal of Ayub Medical College, Abbottabad: JAMC"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199102213240804","article-title":"Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease","volume":"324","author":"Salusky","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ndt\/6.3.170","article-title":"The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study","volume":"6","author":"Schaefer","year":"1991","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0061|cit61","first-page":"785","article-title":"Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"25","author":"Shaheen","year":"2004","journal-title":"Saudi Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5414\/CNP70404","article-title":"Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia","volume":"70","author":"Shigematsu","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.jrn.2007.08.005","article-title":"Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study","volume":"17","author":"Spiegel","year":"2007","journal-title":"Journal of Renal Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2215\/CJN.02830608","article-title":"Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial","volume":"4","author":"Sprague","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CNP72252","article-title":"Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study","volume":"72","author":"Sprague","year":"2009","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006023.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11255-007-9300-0","article-title":"Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial","volume":"40","author":"Tzanakis","year":"2008","journal-title":"International Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/17.2.265","article-title":"An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate","volume":"17","author":"Yang","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic haemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD006023.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance haemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Advances in Renal Replacement Therapy"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2215\/CJN.00950306","article-title":"Phosphate binders: hold the calcium?","volume":"1","author":"Bushinsky","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","article-title":"Pathogenesis of vascular calcification in chronic kidney disease","volume":"68","author":"Cozzolino","year":"2005","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1440-1797.2006.00508.x","article-title":"The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.","volume":"11 Suppl 1","author":"Elder","year":"2006","journal-title":"Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD006023.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2215\/CJN.01831105","article-title":"Calcium-based phosphate binders are appropriate in chronic renal failure","volume":"1","author":"Friedman","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD006023.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7414","key":"10.1002\/14651858.CD006023.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ki.2009.60","article-title":"Oral phosphate binders","volume":"75","author":"Hutchinson","year":"2009","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/ndt\/gfp350","article-title":"The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis","volume":"24","author":"Jamal","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD006023.pub2-BIB0085|cit85","first-page":"70","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"113","key":"10.1002\/14651858.CD006023.pub2-BIB0086|cit86","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","journal-title":"Kidney International - Supplement"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch6"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","article-title":"A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States","volume":"66","author":"Manns","year":"2004","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/ndt\/gfm367","article-title":"Economic evaluation of sevelamer in patients with end-stage renal disease","volume":"22","author":"Manns","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"22","key":"10.1002\/14651858.CD006023.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/archinternmed.2009.382","article-title":"Annual progression of coronary calcification in trials of preventive therapies: a systematic review","volume":"169","author":"McCullough","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006023.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2215\/CJN.00560206","article-title":"The case against calcium-based phosphate binders","volume":"1","author":"Moe","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.ki.5000020","article-title":"Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats","volume":"69","author":"Nagano","year":"2006","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub3","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006023.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0096|cit96","unstructured":"Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2010, Issue 12. Art. No.: RENAL (accessed December 2010)"},{"issue":"105","key":"10.1002\/14651858.CD006023.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.ki.5001997","article-title":"A new era in phosphate binder therapy: what are the options?","volume":"70","author":"Salusky","year":"2006","journal-title":"Kidney International - Supplement"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CNP63119","article-title":"Cellular and molecular mechanisms of secondary hyperparathyroidism","volume":"63","author":"Silver","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD006023.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.ki.5002527","article-title":"The details bedevil DCOR","volume":"72","author":"Silver","year":"2007","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"Peter","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD006023.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2215\/CJN.04100609","article-title":"Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data","volume":"4","author":"Peter","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD006023.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.ajkd.2005.09.009","article-title":"Hypothesis versus association: the optimal hemoglobin target debate","volume":"46","author":"Strippoli","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"9559","key":"10.1002\/14651858.CD006023.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(07)60165-2","article-title":"Haemoglobin targets: we were wrong, time to move on","volume":"369","author":"Strippoli","year":"2007","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD006023.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMe0901067","article-title":"Sunset for statins after AURORA?","volume":"360","author":"Strippoli","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/030079908X260853","article-title":"An economic evaluation of sevelamer in patients new to dialysis","volume":"24","author":"Taylor","year":"2008","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD006023.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006023.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/ndt\/gfm421","article-title":"Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients","volume":"22","author":"Tonelli","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006023.pub2-BIB0109|cit109","unstructured":"United States Renal Data System (USRDS) Costs of ESRD http:\/\/www.usrds.org\/2009\/pdf\/V2_11_09.pdf (accessed October 2010)"},{"issue":"2","key":"10.1002\/14651858.CD006023.pub2-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006023.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006023.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T21:27:26Z","timestamp":1712179646000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006023.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006023.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006023.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]}}}